Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2019

Open Access 01-12-2019 | Diabetes | Research article

Poor short-term glycemic control in patients with type 2 diabetes impairs the intestinal mucosal barrier: a prospective, single-center, observational study

Authors: Lijuan Shen, Li Ao, Haoben Xu, Junfeng Shi, Dali You, Xiuwen Yu, Weixin Xu, Jie Sun, Fei Wang

Published in: BMC Endocrine Disorders | Issue 1/2019

Login to get access

Abstract

Background

To determine the relation between daily glycemic fluturation and the intestinal mucosal barrier dysfunction in type 2 diabetes mellitus (T2DM).

Methods

Totally 66 patients with T2DM were enrolled, 33 healthy volunteers were also recruited according to the enrolled patients’ gender and age in a ratio of 2: 1. Patients were bisected by the median of endotoxins level into low(< 12.31 μ/l, n = 33) and high(≥12.31 μ/l, n = 33) blood endotoxin groups. Clinical data and blood glucose fluctuations were compared between groups. Multivariate regression analysis was used to determine the independent factors affecting the intestinal mucosal barrier.

Results

Serum endotoxin [12.1 (4.2~22.0) vs 3.2 (1.3~6.0), P < 0.001] and fasting blood glucose levels [9.8 ± 3.6 vs 5.4 ± 0.7, P < 0.001] were significantly higher in patients with T2DM than the control group. The standard deviation of blood glucose (SDBG) within 1 day [2.9 (2.0~3.3) vs. 2.1 (1.6~2.5), P = 0.012] and the largest amplitude of glycemic excursions (LAGE) [7.5 (5.4~8.9) vs. 5.9 (4.3~7.4), P = 0.034] were higher in the high endotoxin group than in the low endotoxin group. A multiple linear stepwise regression revealed a positive correlation between SDBG with endotoxin (standard partial regression coefficient = 0.255, P = 0.039).

Conclusions

T2DM patients who incapable of maintaining stable blood glucose level are at a higher risk to associated with intestinal mucosal barrier injury.
Literature
1.
go back to reference Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362:1090–101.CrossRef Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362:1090–101.CrossRef
2.
go back to reference Malo MS. A high level of intestinal alkaline phosphatase is protective against type 2 diabetes mellitus irrespective of obesity. EBioMedicine. 2015;2:2016–23.CrossRef Malo MS. A high level of intestinal alkaline phosphatase is protective against type 2 diabetes mellitus irrespective of obesity. EBioMedicine. 2015;2:2016–23.CrossRef
3.
go back to reference Sato J, Kanazawa A, Ikeda F, et al. Gut dysbiosis and detection of "live gut bacteria" in blood of Japanese patients with type 2 diabetes. Diabetes Care. 2014;37(8):2343–50.CrossRef Sato J, Kanazawa A, Ikeda F, et al. Gut dysbiosis and detection of "live gut bacteria" in blood of Japanese patients with type 2 diabetes. Diabetes Care. 2014;37(8):2343–50.CrossRef
4.
go back to reference Zhao H, Li Z, Tian G, et al. Effects of traditional Chinese medicine on rats with type II diabetes induced by high-fat diet and streptozotocin: a urine metabonomic study. Afr Health Sci. 2013;13:673–81.PubMedPubMedCentral Zhao H, Li Z, Tian G, et al. Effects of traditional Chinese medicine on rats with type II diabetes induced by high-fat diet and streptozotocin: a urine metabonomic study. Afr Health Sci. 2013;13:673–81.PubMedPubMedCentral
5.
go back to reference Thaiss CA, Levy M, Grosheva I, et al. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. Science. 2018;359(6382):1376–83. Thaiss CA, Levy M, Grosheva I, et al. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. Science. 2018;359(6382):1376–83.
6.
go back to reference Heron M. Deaths: Leading Causes for 2016. Natl Vital Stat Rep. 2018;67(6):1–77.PubMed Heron M. Deaths: Leading Causes for 2016. Natl Vital Stat Rep. 2018;67(6):1–77.PubMed
7.
go back to reference Hayes MT, Foo J, Besic V, et al. Is intestinal gluconeogenesis a key factor in the early changes in glucose homeostasis following gastric bypass? Obes Surg. 2011;21:759–62.CrossRef Hayes MT, Foo J, Besic V, et al. Is intestinal gluconeogenesis a key factor in the early changes in glucose homeostasis following gastric bypass? Obes Surg. 2011;21:759–62.CrossRef
8.
go back to reference Li B1, Zhou X, Wu J, et al. From gut changes to type 2 diabetes remission after gastric bypass surgeries. Front Med. 2013;7:191–200.CrossRef Li B1, Zhou X, Wu J, et al. From gut changes to type 2 diabetes remission after gastric bypass surgeries. Front Med. 2013;7:191–200.CrossRef
9.
go back to reference Koliaki C, Liatis S, le Roux CW, et al. The role of bariatric surgery to treat diabetes: current challenges and perspectives. BMC Endocr Disord. 2017;17(1):50.CrossRef Koliaki C, Liatis S, le Roux CW, et al. The role of bariatric surgery to treat diabetes: current challenges and perspectives. BMC Endocr Disord. 2017;17(1):50.CrossRef
10.
go back to reference Scaldaferri F, Pizzoferrato M, Gerardi V, et al. The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol. 2012;46(Suppl):S12–7.CrossRef Scaldaferri F, Pizzoferrato M, Gerardi V, et al. The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol. 2012;46(Suppl):S12–7.CrossRef
11.
go back to reference Yang X, Gao XC, Liu J, et al. Effect of EPEC endotoxin and bifidobacteria on intestinal barrier function through modulation of toll-like receptor 2 and toll-like receptor 4 expression in intestinal epithelial cell-18. World J Gastroenterol. 2017;23(26):4744–51.CrossRef Yang X, Gao XC, Liu J, et al. Effect of EPEC endotoxin and bifidobacteria on intestinal barrier function through modulation of toll-like receptor 2 and toll-like receptor 4 expression in intestinal epithelial cell-18. World J Gastroenterol. 2017;23(26):4744–51.CrossRef
12.
go back to reference Al-Attas OS, Al-Daghri NM, Al-Rubeaan K, et al. Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies. Cardiovasc Diabetol. 2009;15:8–20. Al-Attas OS, Al-Daghri NM, Al-Rubeaan K, et al. Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies. Cardiovasc Diabetol. 2009;15:8–20.
13.
go back to reference Creely SJ, McTernan PG, Kusminski CM, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292(3):E740–7.CrossRef Creely SJ, McTernan PG, Kusminski CM, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292(3):E740–7.CrossRef
14.
go back to reference Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489:220–30.CrossRef Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489:220–30.CrossRef
15.
go back to reference Genton L, Cani PD, Schrenzel J. Alterations of gut barrier and gut microbiota in food restriction, food deprivation and protein-energy wasting. Clinl Nutr. 2015;34:341–9.CrossRef Genton L, Cani PD, Schrenzel J. Alterations of gut barrier and gut microbiota in food restriction, food deprivation and protein-energy wasting. Clinl Nutr. 2015;34:341–9.CrossRef
16.
go back to reference Cyphert TJ, Morris RT, House LM, et al. NF-κB-dependent airway inflammation triggers systemic insulin resistance. Am J Physiol Regul Integr Comp Physiol. 2015;309:R1144–52.CrossRef Cyphert TJ, Morris RT, House LM, et al. NF-κB-dependent airway inflammation triggers systemic insulin resistance. Am J Physiol Regul Integr Comp Physiol. 2015;309:R1144–52.CrossRef
17.
go back to reference Kaĭdashev IP. NF-kB activation as a molecular basis of pathological process by metabolic syndrome. Fiziol Zh. 2012;58:93–101.PubMed Kaĭdashev IP. NF-kB activation as a molecular basis of pathological process by metabolic syndrome. Fiziol Zh. 2012;58:93–101.PubMed
18.
go back to reference Ferdaoussi M, Abdelli S, Yang JY, et al. Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway. Diabetes. 2008;57:1205–15.CrossRef Ferdaoussi M, Abdelli S, Yang JY, et al. Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway. Diabetes. 2008;57:1205–15.CrossRef
19.
go back to reference Xu J, Liu Z, Zhan W, et al. Recombinant TsP53 modulates intestinal epithelial barrier integrity via upregulation of ZO-1 in LPS-induced septic mice. Mol Med Rep. 2018;17(1):1212–8.PubMed Xu J, Liu Z, Zhan W, et al. Recombinant TsP53 modulates intestinal epithelial barrier integrity via upregulation of ZO-1 in LPS-induced septic mice. Mol Med Rep. 2018;17(1):1212–8.PubMed
20.
go back to reference Gao X, Miao R, Tao Y, et al. Effect of montmorillonite powder on intestinal mucosal barrier in children with abdominal Henoch-Schonlein purpura: a randomized controlled study. Medicine (Baltimore). 2018;97(39):e12577.CrossRef Gao X, Miao R, Tao Y, et al. Effect of montmorillonite powder on intestinal mucosal barrier in children with abdominal Henoch-Schonlein purpura: a randomized controlled study. Medicine (Baltimore). 2018;97(39):e12577.CrossRef
21.
go back to reference Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of endocrinology on the comprehensive type 2 diabetes management algorithm-2018 executive summary. Endocr Pract. 2018;24:91–120.CrossRef Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of endocrinology on the comprehensive type 2 diabetes management algorithm-2018 executive summary. Endocr Pract. 2018;24:91–120.CrossRef
22.
go back to reference American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. 2014;37(Suppl 1):S14–80. American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. 2014;37(Suppl 1):S14–80.
23.
go back to reference Zhong H, Yuan Y, Xie W, et al. Type 2 Diabetes Mellitus Is Associated with More Serious Small Intestinal Mucosal Injuries. PLoS ONE. 11(9):e0162354. Zhong H, Yuan Y, Xie W, et al. Type 2 Diabetes Mellitus Is Associated with More Serious Small Intestinal Mucosal Injuries. PLoS ONE. 11(9):e0162354.
24.
go back to reference Horton F, Wright J, Smith L, et al. Short Report: Pathophysiology Increased intestinal permeability to oral chromium (51Cr)-EDTA in human Type 2 diabetes. Diabet Med. 2014;31:559–63.CrossRef Horton F, Wright J, Smith L, et al. Short Report: Pathophysiology Increased intestinal permeability to oral chromium (51Cr)-EDTA in human Type 2 diabetes. Diabet Med. 2014;31:559–63.CrossRef
25.
go back to reference Zhao L, Luo L, Jia W, et al. Serum diamine oxidase as a hemorrhagic shock biomarker in a rabbit model. PLoS One. 2014;9(8):e102285.CrossRef Zhao L, Luo L, Jia W, et al. Serum diamine oxidase as a hemorrhagic shock biomarker in a rabbit model. PLoS One. 2014;9(8):e102285.CrossRef
26.
go back to reference Bragg LE, Thompson JS, West WW. Intestinal diamine oxidase levels reflect ischemic injury. J Surg Res. 1991;50(3):228–33.CrossRef Bragg LE, Thompson JS, West WW. Intestinal diamine oxidase levels reflect ischemic injury. J Surg Res. 1991;50(3):228–33.CrossRef
27.
go back to reference Yee SW, Lin L, Merski M, et al. Prediction and validation of enzyme and transporter off-targets for metformin. J Pharmacokinet Pharmacodyn. 2015;42(5):463–75.CrossRef Yee SW, Lin L, Merski M, et al. Prediction and validation of enzyme and transporter off-targets for metformin. J Pharmacokinet Pharmacodyn. 2015;42(5):463–75.CrossRef
28.
go back to reference Demircan M, Cetin S, Uguralp S, et al. Plasma D-lactic acid level: a useful marker to distinguish perforated from acute simple appendicitis. Asian J Surg. 2004;27(4):303–5.CrossRef Demircan M, Cetin S, Uguralp S, et al. Plasma D-lactic acid level: a useful marker to distinguish perforated from acute simple appendicitis. Asian J Surg. 2004;27(4):303–5.CrossRef
29.
go back to reference Sun XQ, Fu XB, Zhang R, et al. Relationship between plasma D(−)-lactate and intestinal damage after severe injuries in rats. World J Gastroenterol. 2001;7(4):555–8.CrossRef Sun XQ, Fu XB, Zhang R, et al. Relationship between plasma D(−)-lactate and intestinal damage after severe injuries in rats. World J Gastroenterol. 2001;7(4):555–8.CrossRef
30.
go back to reference McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426–35.CrossRef McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426–35.CrossRef
31.
go back to reference Cavaillon JM. Exotoxins and endotoxins: inducers of inflammatory cytokines. Toxicon. 2018;149:45–53.CrossRef Cavaillon JM. Exotoxins and endotoxins: inducers of inflammatory cytokines. Toxicon. 2018;149:45–53.CrossRef
32.
go back to reference Wu X, Ma C, Han L, et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol. 2010;61:69–78.CrossRef Wu X, Ma C, Han L, et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol. 2010;61:69–78.CrossRef
33.
go back to reference Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–72.CrossRef Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–72.CrossRef
34.
go back to reference Al-Obaide MAI, Singh R, Datta P, et al. Gut Microbiota-Dependent Trimethylamine-N-oxide and Serum Biomarkers in Patients with T2DM and Advanced CKD. J Clin Med. 2017;6(9). Al-Obaide MAI, Singh R, Datta P, et al. Gut Microbiota-Dependent Trimethylamine-N-oxide and Serum Biomarkers in Patients with T2DM and Advanced CKD. J Clin Med. 2017;6(9).
35.
go back to reference Wu N, Shen H, Liu H, et al. Acute blood glucose fluctuation enhances rat aorta endothelial cell apoptosis, oxidative stress and pro-inflammatory cytokine expression in vivo. Cardiovasc Diabetol. 2016;15:109.CrossRef Wu N, Shen H, Liu H, et al. Acute blood glucose fluctuation enhances rat aorta endothelial cell apoptosis, oxidative stress and pro-inflammatory cytokine expression in vivo. Cardiovasc Diabetol. 2016;15:109.CrossRef
36.
go back to reference Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, et al. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014;5:444–70.CrossRef Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, et al. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014;5:444–70.CrossRef
37.
go back to reference Jayashree B, Bibin YS, Prabhu D, et al. Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Mol Cell Biochem. 2014;388(1–2):203–10.CrossRef Jayashree B, Bibin YS, Prabhu D, et al. Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Mol Cell Biochem. 2014;388(1–2):203–10.CrossRef
38.
go back to reference Oliveira RB, Canuto LP, Collares-Buzato CB. Intestinal luminal content from high-fat-fed prediabetic mice changes epithelial barrier function in vitro. Life Sci. 2019;216:10–21.CrossRef Oliveira RB, Canuto LP, Collares-Buzato CB. Intestinal luminal content from high-fat-fed prediabetic mice changes epithelial barrier function in vitro. Life Sci. 2019;216:10–21.CrossRef
Metadata
Title
Poor short-term glycemic control in patients with type 2 diabetes impairs the intestinal mucosal barrier: a prospective, single-center, observational study
Authors
Lijuan Shen
Li Ao
Haoben Xu
Junfeng Shi
Dali You
Xiuwen Yu
Weixin Xu
Jie Sun
Fei Wang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2019
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-019-0354-7

Other articles of this Issue 1/2019

BMC Endocrine Disorders 1/2019 Go to the issue